Abingworth LLP Cyma Bay Therapeutics, Inc. Transaction History
Abingworth LLP
- $301 Million
- Q4 2022
A detailed history of Abingworth LLP transactions in Cyma Bay Therapeutics, Inc. stock. As of the latest transaction made, Abingworth LLP holds 131,036 shares of CBAY stock, worth $0. This represents 0.27% of its overall portfolio holdings.
Number of Shares
131,036
Previous 131,036
-0.0%
Holding current value
$0
Previous $457,000
79.65%
% of portfolio
0.27%
Previous 0.16%
Shares
4 transactions
Others Institutions Holding CBAY
# of Institutions
11Shares Held
1.88MCall Options Held
0Put Options Held
0-
Foresite Capital Management Iii, LLC Larkspur, CA1.64MShares$015.17% of portfolio
-
Golden State Equity Partners South Coast Metro, CA54.3KShares$00.32% of portfolio
-
Connacht Asset Management LP New York, NY12KShares$01.09% of portfolio
-
Ctc Capital Management, LLC10.7KShares$00.2% of portfolio
-
Pictet Asset Management Sa Geneva 73, V810.6KShares$00.0% of portfolio
About CymaBay Therapeutics, Inc.
- Ticker CBAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 84,677,904
- Description
- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...